{"2020-07-01": [{"url": "https://cloud.iexapis.com/v1/news/article/9f6d6e38-5c92-46bb-b8b8-2b8a13564af6", "summary": "The summer will be a critical time for the race to develop effective coronavirus treatments and vaccines. Business Insider identified the nine most important events expected to happen in July. Expect a flood of data this month from vaccine and drug programs wrapping up clinical trials. Other promising therapeutics and vaccines are aiming to start human testing. And the speediest vaccine programs, like Moderna's, will soon start massive late-stage trials \u2014 the crucial test in seeing how well these experimental shots work in humans. Visit Business Insider's homepage for more stories . The dog days of summer are shaping into a critical stretch for developing COVID-19 drugs and vaccines. There are hundreds of research efforts across the world hunting for a potential cure. Business Insider reviewed what's underway and identified the nine most important events slated for July. That includes potential vaccines from drugmakers like Johnson & Johnson starting human testing, while those that are farther along like Moderna's experimental vaccine should be disclosing detailed results and even starting late-stage studies.", "lang": "en", "hasPaywall": false, "sentiment": {"neg": 0.0, "neu": 1.0, "pos": 0.0, "compound": 0.0}}, {"url": "https://cloud.iexapis.com/v1/news/article/9f6d6e38-5c92-46bb-b8b8-2b8a13564af6", "summary": "The summer will be a critical time for the race to develop effective coronavirus treatments and vaccines. Business Insider identified the nine most important events expected to happen in July. Expect a flood of data this month from vaccine and drug programs wrapping up clinical trials. Other promising therapeutics and vaccines are aiming to start human testing. And the speediest vaccine programs, like Moderna's, will soon start massive late-stage trials \u2014 the crucial test in seeing how well these experimental shots work in humans. Visit Business Insider's homepage for more stories . The dog days of summer are shaping into a critical stretch for developing COVID-19 drugs and vaccines. There are hundreds of research efforts across the world hunting for a potential cure. Business Insider reviewed what's underway and identified the nine most important events slated for July. That includes potential vaccines from drugmakers like Johnson & Johnson starting human testing, while those that are farther along like Moderna's experimental vaccine should be disclosing detailed results and even starting late-stage studies.", "lang": "en", "hasPaywall": false, "sentiment": {"neg": 0.0, "neu": 1.0, "pos": 0.0, "compound": 0.0}}, {"url": "https://cloud.iexapis.com/v1/news/article/9f6d6e38-5c92-46bb-b8b8-2b8a13564af6", "summary": "The summer will be a critical time for the race to develop effective coronavirus treatments and vaccines. Business Insider identified the nine most important events expected to happen in July. Expect a flood of data this month from vaccine and drug programs wrapping up clinical trials. Other promising therapeutics and vaccines are aiming to start human testing. And the speediest vaccine programs, like Moderna's, will soon start massive late-stage trials \u2014 the crucial test in seeing how well these experimental shots work in humans. Visit Business Insider's homepage for more stories . The dog days of summer are shaping into a critical stretch for developing COVID-19 drugs and vaccines. There are hundreds of research efforts across the world hunting for a potential cure. Business Insider reviewed what's underway and identified the nine most important events slated for July. That includes potential vaccines from drugmakers like Johnson & Johnson starting human testing, while those that are farther along like Moderna's experimental vaccine should be disclosing detailed results and even starting late-stage studies.", "lang": "en", "hasPaywall": false, "sentiment": {"neg": 0.0, "neu": 1.0, "pos": 0.0, "compound": 0.0}}, {"url": "https://cloud.iexapis.com/v1/news/article/9f6d6e38-5c92-46bb-b8b8-2b8a13564af6", "summary": "The summer will be a critical time for the race to develop effective coronavirus treatments and vaccines. Business Insider identified the nine most important events expected to happen in July. Expect a flood of data this month from vaccine and drug programs wrapping up clinical trials. Other promising therapeutics and vaccines are aiming to start human testing. And the speediest vaccine programs, like Moderna's, will soon start massive late-stage trials \u2014 the crucial test in seeing how well these experimental shots work in humans. Visit Business Insider's homepage for more stories . The dog days of summer are shaping into a critical stretch for developing COVID-19 drugs and vaccines. There are hundreds of research efforts across the world hunting for a potential cure. Business Insider reviewed what's underway and identified the nine most important events slated for July. That includes potential vaccines from drugmakers like Johnson & Johnson starting human testing, while those that are farther along like Moderna's experimental vaccine should be disclosing detailed results and even starting late-stage studies.", "lang": "en", "hasPaywall": false, "sentiment": {"neg": 0.0, "neu": 1.0, "pos": 0.0, "compound": 0.0}}, {"url": "https://cloud.iexapis.com/v1/news/article/9f6d6e38-5c92-46bb-b8b8-2b8a13564af6", "summary": "The summer will be a critical time for the race to develop effective coronavirus treatments and vaccines. Business Insider identified the nine most important events expected to happen in July. Expect a flood of data this month from vaccine and drug programs wrapping up clinical trials. Other promising therapeutics and vaccines are aiming to start human testing. And the speediest vaccine programs, like Moderna's, will soon start massive late-stage trials \u2014 the crucial test in seeing how well these experimental shots work in humans. Visit Business Insider's homepage for more stories . The dog days of summer are shaping into a critical stretch for developing COVID-19 drugs and vaccines. There are hundreds of research efforts across the world hunting for a potential cure. Business Insider reviewed what's underway and identified the nine most important events slated for July. That includes potential vaccines from drugmakers like Johnson & Johnson starting human testing, while those that are farther along like Moderna's experimental vaccine should be disclosing detailed results and even starting late-stage studies.", "lang": "en", "hasPaywall": false, "sentiment": {"neg": 0.0, "neu": 1.0, "pos": 0.0, "compound": 0.0}}, {"url": "https://cloud.iexapis.com/v1/news/article/9f6d6e38-5c92-46bb-b8b8-2b8a13564af6", "summary": "The summer will be a critical time for the race to develop effective coronavirus treatments and vaccines. Business Insider identified the nine most important events expected to happen in July. Expect a flood of data this month from vaccine and drug programs wrapping up clinical trials. Other promising therapeutics and vaccines are aiming to start human testing. And the speediest vaccine programs, like Moderna's, will soon start massive late-stage trials \u2014 the crucial test in seeing how well these experimental shots work in humans. Visit Business Insider's homepage for more stories . The dog days of summer are shaping into a critical stretch for developing COVID-19 drugs and vaccines. There are hundreds of research efforts across the world hunting for a potential cure. Business Insider reviewed what's underway and identified the nine most important events slated for July. That includes potential vaccines from drugmakers like Johnson & Johnson starting human testing, while those that are farther along like Moderna's experimental vaccine should be disclosing detailed results and even starting late-stage studies.", "lang": "en", "hasPaywall": false, "sentiment": {"neg": 0.0, "neu": 1.0, "pos": 0.0, "compound": 0.0}}, {"url": "https://cloud.iexapis.com/v1/news/article/9f6d6e38-5c92-46bb-b8b8-2b8a13564af6", "summary": "The summer will be a critical time for the race to develop effective coronavirus treatments and vaccines. Business Insider identified the nine most important events expected to happen in July. Expect a flood of data this month from vaccine and drug programs wrapping up clinical trials. Other promising therapeutics and vaccines are aiming to start human testing. And the speediest vaccine programs, like Moderna's, will soon start massive late-stage trials \u2014 the crucial test in seeing how well these experimental shots work in humans. Visit Business Insider's homepage for more stories . The dog days of summer are shaping into a critical stretch for developing COVID-19 drugs and vaccines. There are hundreds of research efforts across the world hunting for a potential cure. Business Insider reviewed what's underway and identified the nine most important events slated for July. That includes potential vaccines from drugmakers like Johnson & Johnson starting human testing, while those that are farther along like Moderna's experimental vaccine should be disclosing detailed results and even starting late-stage studies.", "lang": "en", "hasPaywall": false, "sentiment": {"neg": 0.0, "neu": 1.0, "pos": 0.0, "compound": 0.0}}, {"url": "https://cloud.iexapis.com/v1/news/article/9f6d6e38-5c92-46bb-b8b8-2b8a13564af6", "summary": "The summer will be a critical time for the race to develop effective coronavirus treatments and vaccines. Business Insider identified the nine most important events expected to happen in July. Expect a flood of data this month from vaccine and drug programs wrapping up clinical trials. Other promising therapeutics and vaccines are aiming to start human testing. And the speediest vaccine programs, like Moderna's, will soon start massive late-stage trials \u2014 the crucial test in seeing how well these experimental shots work in humans. Visit Business Insider's homepage for more stories . The dog days of summer are shaping into a critical stretch for developing COVID-19 drugs and vaccines. There are hundreds of research efforts across the world hunting for a potential cure. Business Insider reviewed what's underway and identified the nine most important events slated for July. That includes potential vaccines from drugmakers like Johnson & Johnson starting human testing, while those that are farther along like Moderna's experimental vaccine should be disclosing detailed results and even starting late-stage studies.", "lang": "en", "hasPaywall": false, "sentiment": {"neg": 0.0, "neu": 1.0, "pos": 0.0, "compound": 0.0}}], "2020-06-30": [{"url": "https://cloud.iexapis.com/v1/news/article/6fa87b28-569f-4145-a18d-f6ce1d39f9bd", "summary": "Inovio has rallied 860% year-to-date as investors bid up the company's stock in hopes of the successful development of a vaccine for COVID-19. On Tuesday, Inovio fell as much as 17.8% after the company released early Phase I data on its INO-4800 COVID-19 vaccine. The company said 94% of Phase I participants demonstrated an immune response to the vaccine candidate. Inovio said its vaccine candidate was selected to participate in a non-human primate study as part of the US government's Operation Warp Speed. Visit Business Insider's homepage for more stories . Inovio's Tuesday morning release of early-stage data on its COVID-19 vaccine candidate sent shares lower by as much as 17.8%, giving the stock a breather after it rallied 860% year-to-date as of Monday's close. Investors have bid up the company on hopes that its vaccine candidate for COVID-19 proves successful in human trials. The interim Phase 1 data from Inovio showed that 94% of trial participants demonstrated overall immune response at week six after two doses of INO-4800, according to the company.", "lang": "en", "hasPaywall": false, "sentiment": {"neg": 0.0, "neu": 0.947, "pos": 0.053, "compound": 0.1531}}], "2020-06-29": [{"url": "https://cloud.iexapis.com/v1/news/article/f19554d7-7db3-4041-8291-1473fb533f09", "summary": "NEW YORK, June 29, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BHTG, VXRT, COTY, BLNK, and SHIP. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link\u2026.", "lang": "en", "hasPaywall": false, "sentiment": {"neg": 0.113, "neu": 0.887, "pos": 0.0, "compound": -0.3182}}], "2020-06-28": [{"url": "https://cloud.iexapis.com/v1/news/article/b85c2cc2-236c-474e-99d5-2d69fc5eef4f", "summary": "Biotech stocks went on a seesaw ride along with the broader markets in the week ended June 26. Yet there were some encouraging developments on the COVID-19 vaccine development front. Vaccine companies are going all out, forging alliances and adding personnel that could help them be successful in their quest. Translate Bio Inc (NASDAQ: TBIO ) rallied strongly earlier in the week on the back of news concerning an expansion of its vaccine development partnership with Sanofi SA (NASDAQ: SNY ) but eventually gave back some of the gains following a secondary offering. Vaxart Inc (NASDAQ: VXRT ), another COVID-19 vaccine play , rallied during the week. The FDA review machinery worked overtime, ruling on a host of investigational therapies. Three biopharma companies went public this week, raising a combined $485 million in gross proceeds. The following are key catalysts in the unfolding week: Conferences Cantor Fitzgerald's Virtual Symposium: \"Winning Ways to Treat Infections and COVID-19: Tuesday, June \u2026", "lang": "en", "hasPaywall": false, "sentiment": {"neg": 0.0, "neu": 0.863, "pos": 0.137, "compound": 0.775}}], "2020-06-26": [{"url": "https://cloud.iexapis.com/v1/news/article/823635ef-c08d-4b75-bed1-d28850caeb1f", "summary": "The Trump administration's coronavirus vaccine program, called Operation Warp Speed, has been shrouded in secrecy since launching in May. Some tiny biotechs have started to announce they have been selected as part of Operation Warp Speed, sending their stocks soaring. The government has said that Operation Warp Speed selected 14 vaccine research programs, but it has declined to specify which companies are involved. Warp Speed is the federal government's effort to have 300 million doses of a safe and effective vaccine by January 2021. Visit Business Insider's homepage for more stories . On Friday, a tiny San Francisco biotech made a bold claim. The biotech called Vaxart said it was chosen by Operation Warp Speed, an effort from the Trump administration to speed up work on a coronavirus vaccine and make an immunization broadly available by early next year. In reality, its vaccine candidate has just been selected for early research in primates. Other major companies are already testing coronavirus vaccines in people.", "lang": "en", "hasPaywall": false, "sentiment": {"neg": 0.047, "neu": 0.857, "pos": 0.096, "compound": 0.9189}}, {"url": "https://cloud.iexapis.com/v1/news/article/b7192c74-37bd-4dd3-92f1-55e63a10736b", "summary": "The coronavirus vaccine maker will participate in a government-funded study.", "lang": "en", "hasPaywall": false, "sentiment": {"neg": 0.0, "neu": 0.884, "pos": 0.116, "compound": 0.9855}}, {"url": "https://cloud.iexapis.com/v1/news/article/c581174f-d19c-4433-a043-630d804631e3", "summary": "Vaxart, a small-cap biotechnology company focused on developing oral vaccines administered by tablet rather than injection, said on Friday that \u2026", "lang": "en", "hasPaywall": false, "sentiment": {"neg": 0.0, "neu": 0.95, "pos": 0.05, "compound": 0.8885}}, {"url": "https://cloud.iexapis.com/v1/news/article/b1a91d18-b99c-4b08-837e-eb5888865885", "summary": "Shares of oral vaccine maker Vaxart Inc (NASDAQ: VXRT ) are on a strong two-day run after two announcements tied to coronavirus vaccine development. What Happened: The South San Francisco, California-based company said its oral COVID-19 vaccine has been selected to participate in a non-human primate challenge study, or animal study, organized and funded by Operation Warp Speed. The study is designed to demonstrate the efficacy of the vaccine candidate, according to Vaxart. \"We are very pleased to be one of the few companies selected by Operation Warp Speed, and that ours is the only oral vaccine being evaluated,\" CEO Andrei Floroiu said in a statement. On Thursday, Vaxart said it signed a memorandum of understanding with Attwill Medical \u2026 Full story available on Benzinga.com", "lang": "en", "hasPaywall": false, "sentiment": {"neg": 0.0, "neu": 0.916, "pos": 0.084, "compound": 0.9287}}], "2020-06-25": [{"url": "https://cloud.iexapis.com/v1/news/article/5f86710d-fb8f-4449-8f5d-e2a53888dc02", "summary": "Investors are piling into coronavirus stocks as COVID-19 cases surge.", "lang": "en", "hasPaywall": false, "sentiment": {"neg": 0.012, "neu": 0.891, "pos": 0.097, "compound": 0.8934}}, {"url": "https://cloud.iexapis.com/v1/news/article/b2ee84ba-0569-4112-9826-9f0e7a2509a2", "summary": "NEW YORK, June 25, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for IZEA, VXRT, WKHS, TOPS, and DAL. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link\u2026.", "lang": "en", "hasPaywall": false, "sentiment": {"neg": 0.099, "neu": 0.729, "pos": 0.173, "compound": 0.4084}}], "2020-05-20": [{"url": "https://cloud.iexapis.com/v1/news/article/e76e33e9-d393-4470-b1cb-5c4199970ff7", "summary": "Shares of Kindred Biosciences Inc. (KIN) are rising over 16% in pre-market today, after the company the biopharmaceutical company announced an agreement with Vaxart Inc.", "lang": "en", "hasPaywall": false, "sentiment": {"neg": 0.0, "neu": 0.904, "pos": 0.096, "compound": 0.8885}}], "2020-05-15": [{"url": "https://cloud.iexapis.com/v1/news/article/c74472e3-1b50-4c9a-a632-94d6d58b1300", "summary": "Dr Sean Tucker, chief scientific officer at Vaxart, has revealed that his company is trialling several vaccine tablets, which could be trailed in humans as early as July", "lang": "en", "hasPaywall": false, "sentiment": {"neg": 0.0, "neu": 1.0, "pos": 0.0, "compound": 0.0}}], "2020-04-28": [{"url": "https://cloud.iexapis.com/v1/news/article/269b0aa7-db1b-451d-81ca-84fe8c896008", "summary": "Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 27) AstraZeneca plc (NYSE: AZN ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Arcturus Therapeutics Ltd (NASDAQ: ARCT ) Avadel Pharmaceuticals PLC (NASDAQ: AVDL ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) BioSig Technologies Inc (NASDAQ: BSGM ) Black Diamond Therapeutics Inc (NASDAQ: BDTX ) Cytosorbents Corp (NASDAQ: CTSO ) DexCom, Inc. (NASDAQ: DXCM ) Erytech Pharma SA (NASDAQ: ERYP ) Exelixis, Inc. (NASDAQ: EXEL ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) I-Mab ADR (NASDAQ: IMAB ) Imara Inc (NASDAQ: IMRA ) Incyte Corporation (NASDAQ: INCY ) Kala Pharmaceuticals Inc (NASDAQ: KALA ) Keros Therapeutics Inc (NASDAQ: KROS ) Masimo Corporation (NASDAQ: MASI ) Novo Nordisk A/S (NYSE: NVO ) OraSure Technologies, Inc. (NASDAQ: OSUR ) Quidel Corporation (NASDAQ: QDEL ) REDHILL BIOPHAR/S ADR (NASDAQ: RDHL ) Repligen Corporation (NASDAQ: RGEN ) Seattle Genetics, Inc. (NASDAQ: SGEN ) Translate Bio Inc (NASDAQ: TBIO ) Ultragenyx Pharmaceutical Inc (NASDAQ: RARE ) Vaxart Inc (NASDAQ: VXRT ) Vermillion, Inc. (NASDAQ: VRML ) West Pharmaceutical Services Inc. (NYSE: WST ) Y-mAbs Therapeutics, Inc (NASDAQ: YMAB ) Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL ) Zynex Inc. (NASDAQ: ZYXI ) None of the Nasdaq- or NYSE-listed biotech/medical device/diagnostics company hit 52-week lows Monday.", "lang": "en", "hasPaywall": false, "sentiment": {"neg": 0.009, "neu": 0.969, "pos": 0.022, "compound": 0.34}}], "2020-04-22": [{"url": "https://cloud.iexapis.com/v1/news/article/29e4080e-5f6a-439c-8e73-c6f260f7709e", "summary": "Vaxart's (VXRT) several COVID-19 vaccine candidates generate immune responses in pre-clinical studies. Stock rises.", "lang": "en", "hasPaywall": false, "sentiment": {"neg": 0.012, "neu": 0.854, "pos": 0.134, "compound": 0.9732}}], "2020-04-21": [{"url": "https://cloud.iexapis.com/v1/news/article/35724fea-356c-497e-9b22-cdfdac62066d", "summary": "Biotech Vaxart (VXRT) has announced positive pre-clinical results for its oral COVID-19 vaccine candidates, with several of the vaccine candidates generating immune responses \u2026 The post Pre-Market: Vaxart Pops 35% On Positive Covid-19 Vaccine Data appeared first on Smarter Analyst .", "lang": "en", "hasPaywall": false, "sentiment": {"neg": 0.0, "neu": 0.914, "pos": 0.086, "compound": 0.9413}}], "2020-04-01": [{"url": "https://cloud.iexapis.com/v1/news/article/e019f4ae-8bae-4125-9363-d7b4e799f95e", "summary": "The quarter was brutal to say the least for most asset classes amid the coronavirus (COVID-19) pandemic. The S&P 500 Index was down about 20% for the quarter. Amid the market mayhem, some health care stocks defied the downturn, thanks to announcements concerning development of drug/vaccine/diagnostic tests for new coronavirus. Focusing on biotechs (leaving out diagnostics stocks), here the top five winners and losers for the quarter. Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter . The Winners Genprex Inc (NASDAQ: GNPX ): (+656.25%) After ending 2019 in penny stock territory, shares of this gene therapy company began to gain ground after the company announced Fast Track Designation for its immunogene therapy in combination with AstraZeneca's (NYSE: AZN ) Tagrisso for treating lung cancer. The momentum accelerated after it signed an exclusive agreement to license a diabetes gene therapy from the University of Pittsburgh.", "lang": "en", "hasPaywall": false, "sentiment": {"neg": 0.0, "neu": 0.876, "pos": 0.124, "compound": 0.5859}}], "2020-03-18": [{"url": "https://cloud.iexapis.com/v1/news/article/1b2e108c-ebc9-4772-92c5-ed0ffa1dd848", "summary": "Vaxart Inc (NASDAQ: VXRT ) shares were advancing Wednesday following an update from the company on its COVID-19 vaccine program. Vaxart said it has entered into an agreement with Emergent Biosolutions Inc (NYSE: EBS ) that will allow Emergent to deploy its molecule-to-market contract development and manufacturing services to develop and manufacture Vaxart's oral vaccine candidate for COVID-19. The oral recombinant vaccine candidate is based on Vaxart's proprietary VAAST platform, according to the company. Benzinga is covering every \u2026 Full story available on Benzinga.com", "lang": "en", "hasPaywall": false, "sentiment": {"neg": 0.0, "neu": 0.863, "pos": 0.137, "compound": 0.9584}}], "2020-02-12": [{"url": "https://cloud.iexapis.com/v1/news/article/12d4c8a2-eb38-4a8a-a5ec-27f50896a4b7", "summary": "Fear and uncertainty have gripped the global population as the number of confirmed coronavirus cases grows daily. What started in Wuhan, the capital of China\u2019s Hubei province, has now spread to 43,101 people in 25 different countries, according to the World Health Organization (WHO), killing over 1,000. While 75% of the infections have occurred in the Hubei province, a worldwide effort to contain the virus, now deemed as COVID-19 by WHO, is underway. These efforts include a two-day forum to create a \u201cglobal research agenda\u201d as well as quarantining individuals returning from the virus\u2019 epicenter for 14 days, with the first 195 U.S. citizens under quarantine being released on February 11. The Centers for Disease Control and Prevention (CDC) has confirmed that 13 people in the U.S. have been infected, with the most recent case in San Diego after a repatriated individual that originally tested negative for the virus developed symptoms. As so much about COVID-19 remains unknown, it has become a race against the clock to find solutions.", "lang": "en", "hasPaywall": false, "sentiment": {"neg": 0.006, "neu": 0.926, "pos": 0.068, "compound": 0.9231}}], "2020-02-03": [{"url": "https://cloud.iexapis.com/v1/news/article/0ba41cce-e96a-4929-8720-dcfef62f23e4", "summary": "Vaxart (VXRT) begins a program to develop a vaccine candidate to counter the new coronavirus infection. Shares jump.", "lang": "en", "hasPaywall": false, "sentiment": {"neg": 0.013, "neu": 0.884, "pos": 0.102, "compound": 0.9274}}], "2020-01-31": [{"url": "https://cloud.iexapis.com/v1/news/article/eb9c0381-01d0-4296-bdaa-c6f05ee976fe", "summary": "Shares of Vaxart Inc. rocketed 54% on heavy volume in afternoon trading, putting them on track for the first close above the $1 mark in nearly 10 months,\u2026", "lang": "en", "hasPaywall": false, "sentiment": {"neg": 0.025, "neu": 0.877, "pos": 0.098, "compound": 0.9022}}], "2019-11-12": [{"url": "https://cloud.iexapis.com/v1/news/article/e4a59d22-8956-43ee-a269-ce2b1c991761", "summary": "Vaxart Inc (NASDAQ:VXRT) has been assigned a consensus broker rating score of 1.00 (Strong Buy) from the two brokers that provide coverage for the stock, Zacks Investment Research reports. Two analysts have rated the stock with a strong buy rating. Brokers have set a 12-month consensus target price of $4.00 for the company and are [\u2026]", "lang": "en", "hasPaywall": false, "sentiment": {"neg": 0.038, "neu": 0.891, "pos": 0.071, "compound": 0.9759}}, {"url": "https://cloud.iexapis.com/v1/news/article/19c00702-4dbb-46e5-a625-086a0bbcf4ea", "summary": "Vaxart Inc (NASDAQ:VXRT) major shareholder Armistice Capital Master Fund acquired 200,000 shares of the company\u2019s stock in a transaction that occurred on Thursday, November 7th. The stock was bought at an average cost of $0.35 per share, with a total value of $70,000.00. Major shareholders that own 10% or more of a company\u2019s stock are [\u2026]", "lang": "en", "hasPaywall": false, "sentiment": {"neg": 0.038, "neu": 0.891, "pos": 0.071, "compound": 0.9717}}], "2019-11-06": [{"url": "https://cloud.iexapis.com/v1/news/article/0f4db42f-544d-4375-9880-cf3cb1f8fa87", "summary": "PDF Version Norovirus represents a $3+billion U.S. market opportunity SOUTH SAN FRANCISCO, Calif., Nov. 06, 2019 -- Vaxart, Inc. , a clinical-stage biotechnology company\u2026 | November 6, 2019", "lang": "en", "hasPaywall": false, "sentiment": {"neg": 0.027, "neu": 0.892, "pos": 0.081, "compound": 0.9746}}], "2019-09-26": [{"url": "https://cloud.iexapis.com/v1/news/article/a207e266-e6be-4315-93f6-94acade52f80", "summary": "The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Sept. 25.) Coherus Biosciences Inc (NASDAQ: CHRS ) The Medicines Company (NASDAQ: MDCO ) Down In The Dumps (Biotech stocks that hit 52-week lows Sept. 25.) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) Advaxis, Inc. (NASDAQ: ADXS ) AnaptysBio Inc (NASDAQ: ANAB ) Aridis Pharmaceuticals Inc (NASDAQ: ARDS ) AzurRx BioPharma Inc (NASDAQ: AZRX ) ( announced lackadaisical efficacy data for pancreatic insufficiency drug) BridgeBio Pharma Inc (NASDAQ: BBIO ) Calithera Biosciences Inc (NASDAQ: CALA ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Catalyst Biosciences Inc (NASDAQ: CBIO ) Cellectis SA (NASDAQ: CLLS ) CytomX Therapeutics Inc (NASDAQ: CTMX ) DelMar Pharmaceuticals Inc (NASDAQ: DMPI ) Eloxx Pharmaceuticals Inc (NASDAQ: ELOX ) Exagen Inc (NASDAQ: XGN ) (IPOed on Sep. 16) Five Prime Therapeutics Inc (NASDAQ: FPRX ) Fulcrum Therapeutics Inc (NASDAQ: FULC ) Gemphire Therapeutics Inc (NASDAQ: GEMP ) Kalvista Pharmaceuticals Inc (NASDAQ: KALV ) Kiniksa Pharmaceuticals Ltd (NASDAQ: KNSA ) Myovant Sciences Ltd (NYSE: MYOV ) Neon Therapeutics Inc (NASDAQ: NTGN ) Novelion Therapeutics Inc (NASDAQ: NVLN ) Nuvectra Corp (NASDAQ: NVTR ) Onconova Therapeutics Inc (NASDAQ: ONTX ) PDS Biotechnology Corp (NASDAQ: PDSB ) Plus Therapeutics Inc (NASDAQ: PSTV ) Sarepta Therapeutics Inc (NASDAQ: SRPT ) Seelos Therapeutics Inc (NASDAQ: SEEL ) Sophiris Bio Inc (NASDAQ: SPHS ) Spring Bank Pharmaceuticals Inc (NASDAQ: SBPH ) Stealth BioTherapeutics Corp (NASDAQ: MITO ) Surface Oncology Inc (NASDAQ: SURF ) Tocagen Inc (NASDAQ: TOCA ) Titan Pharmaceuticals, Inc. (NASDAQ: TTNP ) Urogen Pharma Ltd (NASDAQ: URGN ) Vaxart Inc (NASDAQ: VXRT ) (announced positive topline results for an early-stage \u2026", "lang": "en", "hasPaywall": false, "sentiment": {"neg": 0.0, "neu": 0.76, "pos": 0.24, "compound": 0.743}}], "2019-08-08": [{"url": "https://cloud.iexapis.com/v1/news/article/1ef0184c-6f27-4bb7-bfa9-2ea9439d86c2", "summary": "Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 7) Akero Therapeutics Inc (NASDAQ: AKRO ) Allakos Inc (NASDAQ: ALLK ) Cytokinetics, Inc. (NASDAQ: CYTK ) Guardant Health Inc (NASDAQ: GH ) (reacted to strong second-quarter results) Morphic Holding Inc (NASDAQ: MORF ) West Pharmaceutical Services Inc. (NYSE: WST ) Down In The Dumps (Biotech stocks hitting 52-week lows on Aug. 7) ABIOMED, Inc. (NASDAQ: ABMD ) Assertio Therapeutics Inc (NASDAQ: ASRT ) Bellicum Pharmaceuticals Inc (NASDAQ: BLCM ) Bicycle Therapeutics PLC (NASDAQ: BCYC ) BioCardia Inc (NASDAQ: BCDA ) BIOLINERX LTD/S ADR (NASDAQ: BLRX ) Biopharmx Corp NYSE: (BPMX) CAN-FITE BIOPHA/S ADR (NYSE: CANF ) CELLECT BIOTECH/S ADR (NASDAQ: APOP ) Cellular Biomedicine Group Inc (NASDAQ: CBMG )(reacted to second-quarter results) Eloxx Pharmaceuticals Inc (NASDAQ: ELOX )(reported second-quarter results) Guardion Health Sciences Inc (NASDAQ: GHSI )(announced common stock offering of 9.", "lang": "en", "hasPaywall": false, "sentiment": {"neg": 0.03, "neu": 0.935, "pos": 0.034, "compound": 0.1531}}], "2019-04-16": [{"url": "https://cloud.iexapis.com/beta/news/article/1acd0fa2-4a22-45e4-9e61-6350183a1049", "summary": "No summary available.", "lang": "en", "hasPaywall": false, "sentiment": {"neg": 0.0, "neu": 0.931, "pos": 0.069, "compound": 0.4215}}], "2019-04-08": [{"url": "https://cloud.iexapis.com/beta/news/article/6801d828-f07b-4496-b7c8-2d9dac982ae7", "summary": "No summary available.", "lang": "en", "hasPaywall": false, "sentiment": {"neg": 0.0, "neu": 0.833, "pos": 0.167, "compound": 0.7351}}, {"url": "https://cloud.iexapis.com/beta/news/article/fe7b55b4-d1b5-44f0-890a-f8fb1397006b", "summary": "No summary available.", "lang": "en", "hasPaywall": false, "sentiment": {"neg": 0.067, "neu": 0.868, "pos": 0.065, "compound": -0.0258}}], "2019-03-27": [{"url": "https://cloud.iexapis.com/beta/news/article/18bb57fa-f8ff-4da7-aca8-4e4eb99efa19", "summary": "No summary available.", "lang": "en", "hasPaywall": false, "sentiment": {"neg": 0.0, "neu": 1.0, "pos": 0.0, "compound": 0.0}}], "2019-03-20": [{"url": "https://cloud.iexapis.com/beta/news/article/69b997b9-d266-482b-9752-02211925e0b8", "summary": "No summary available.", "lang": "en", "hasPaywall": false, "sentiment": {"neg": 0.095, "neu": 0.769, "pos": 0.135, "compound": 0.0772}}], "2020-07-07": {}, "2020-07-06": {}, "2020-07-05": {}, "2020-07-04": {}, "2020-07-03": {}, "2020-07-02": {}, "2020-06-27": {}, "2020-06-24": {}, "2020-06-23": {}, "2020-06-22": {}, "2020-06-21": {}, "2020-06-20": {}, "2020-06-19": {}, "2020-06-18": {}, "2020-06-17": {}, "2020-06-16": {}, "2020-06-15": {}, "2020-06-14": {}, "2020-06-13": {}, "2020-06-12": {}, "2020-06-11": {}, "2020-06-10": {}, "2020-06-09": {}, "2020-06-08": {}, "2020-06-07": {}, "2020-06-06": {}, "2020-06-05": {}, "2020-06-04": {}, "2020-06-03": {}, "2020-06-02": {}, "2020-06-01": {}, "2020-05-31": {}, "2020-05-30": {}, "2020-05-29": {}, "2020-05-28": {}, "2020-05-27": {}, "2020-05-26": {}, "2020-05-25": {}, "2020-05-24": {}, "2020-05-23": {}, "2020-05-22": {}, "2020-05-21": {}, "2020-05-19": {}, "2020-05-18": {}, "2020-05-17": {}, "2020-05-16": {}, "2020-05-14": {}, "2020-05-13": {}, "2020-05-12": {}, "2020-05-11": {}, "2020-05-10": {}, "2020-05-09": {}, "2020-05-08": {}, "2020-05-07": {}, "2020-05-06": {}, "2020-05-05": {}, "2020-05-04": {}, "2020-05-03": {}, "2020-05-02": {}, "2020-05-01": {}, "2020-04-30": {}, "2020-04-29": {}, "2020-04-27": {}, "2020-04-26": {}, "2020-04-25": {}, "2020-04-24": {}, "2020-04-23": {}, "2020-04-20": {}, "2020-04-19": {}, "2020-04-18": {}, "2020-04-17": {}, "2020-04-16": {}, "2020-04-15": {}, "2020-04-14": {}, "2020-04-13": {}, "2020-04-12": {}, "2020-04-11": {}, "2020-04-10": {}, "2020-04-09": {}, "2020-04-08": {}, "2020-04-07": {}, "2020-04-06": {}, "2020-04-05": {}, "2020-04-04": {}, "2020-04-03": {}, "2020-04-02": {}, "2020-03-31": {}, "2020-03-30": {}, "2020-03-29": {}, "2020-03-28": {}, "2020-03-27": {}, "2020-03-26": {}, "2020-03-25": {}, "2020-03-24": {}, "2020-03-23": {}, "2020-03-22": {}, "2020-03-21": {}, "2020-03-20": {}, "2020-03-19": {}, "2020-03-17": {}, "2020-03-16": {}, "2020-03-15": {}, "2020-03-14": {}, "2020-03-13": {}, "2020-03-12": {}, "2020-03-11": {}, "2020-03-10": {}, "2020-03-09": {}, "2020-03-08": {}, "2020-03-07": {}, "2020-03-06": {}, "2020-03-05": {}, "2020-03-04": {}, "2020-03-03": {}, "2020-03-02": {}, "2020-03-01": {}, "2020-02-29": {}, "2020-02-28": {}, "2020-02-27": {}, "2020-02-26": {}, "2020-02-25": {}, "2020-02-24": {}, "2020-02-23": {}, "2020-02-22": {}, "2020-02-21": {}, "2020-02-20": {}, "2020-02-19": {}, "2020-02-18": {}, "2020-02-17": {}, "2020-02-16": {}, "2020-02-15": {}, "2020-02-14": {}, "2020-02-13": {}, "2020-02-11": {}, "2020-02-10": {}, "2020-02-09": {}, "2020-02-08": {}, "2020-02-07": {}, "2020-02-06": {}, "2020-02-05": {}, "2020-02-04": {}, "2020-02-02": {}, "2020-02-01": {}, "2020-01-30": {}, "2020-01-29": {}, "2020-01-28": {}, "2020-01-27": {}, "2020-01-26": {}, "2020-01-25": {}, "2020-01-24": {}, "2020-01-23": {}, "2020-01-22": {}, "2020-01-21": {}, "2020-01-20": {}, "2020-01-19": {}, "2020-01-18": {}, "2020-01-17": {}, "2020-01-16": {}, "2020-01-15": {}, "2020-01-14": {}, "2020-01-13": {}, "2020-01-12": {}, "2020-01-11": {}, "2020-01-10": {}, "2020-01-09": {}, "2020-01-08": {}, "2020-01-07": {}, "2020-01-06": {}, "2020-01-05": {}, "2020-01-04": {}, "2020-01-03": {}, "2020-01-02": {}, "2020-01-01": {}, "2019-12-31": {}, "2019-12-30": {}, "2019-12-29": {}, "2019-12-28": {}, "2019-12-27": {}, "2019-12-26": {}, "2019-12-25": {}, "2019-12-24": {}, "2019-12-23": {}, "2019-12-22": {}, "2019-12-21": {}, "2019-12-20": {}, "2019-12-19": {}, "2019-12-18": {}, "2019-12-17": {}, "2019-12-16": {}, "2019-12-15": {}, "2019-12-14": {}, "2019-12-13": {}, "2019-12-12": {}, "2019-12-11": {}, "2019-12-10": {}, "2019-12-09": {}, "2019-12-08": {}, "2019-12-07": {}, "2019-12-06": {}, "2019-12-05": {}, "2019-12-04": {}, "2019-12-03": {}, "2019-12-02": {}, "2019-12-01": {}, "2019-11-30": {}, "2019-11-29": {}, "2019-11-28": {}, "2019-11-27": {}, "2019-11-26": {}, "2019-11-25": {}, "2019-11-24": {}, "2019-11-23": {}, "2019-11-22": {}, "2019-11-21": {}, "2019-11-20": {}, "2019-11-19": {}, "2019-11-18": {}, "2019-11-17": {}, "2019-11-16": {}, "2019-11-15": {}, "2019-11-14": {}, "2019-11-13": {}, "2019-11-11": {}, "2019-11-10": {}, "2019-11-09": {}, "2019-11-08": {}, "2019-11-07": {}, "2019-11-05": {}, "2019-11-04": {}, "2019-11-03": {}, "2019-11-02": {}, "2019-11-01": {}, "2019-10-31": {}, "2019-10-30": {}, "2019-10-29": {}, "2019-10-28": {}, "2019-10-27": {}, "2019-10-26": {}, "2019-10-25": {}, "2019-10-24": {}, "2019-10-23": {}, "2019-10-22": {}, "2019-10-21": {}, "2019-10-20": {}, "2019-10-19": {}, "2019-10-18": {}, "2019-10-17": {}, "2019-10-16": {}, "2019-10-15": {}, "2019-10-14": {}, "2019-10-13": {}, "2019-10-12": {}, "2019-10-11": {}, "2019-10-10": {}, "2019-10-09": {}, "2019-10-08": {}, "2019-10-07": {}, "2019-10-06": {}, "2019-10-05": {}, "2019-10-04": {}, "2019-10-03": {}, "2019-10-02": {}, "2019-10-01": {}, "2019-09-30": {}, "2019-09-29": {}, "2019-09-28": {}, "2019-09-27": {}, "2019-09-25": {}, "2019-09-24": {}, "2019-09-23": {}, "2019-09-22": {}, "2019-09-21": {}, "2019-09-20": {}, "2019-09-19": {}, "2019-09-18": {}, "2019-09-17": {}, "2019-09-16": {}, "2019-09-15": {}, "2019-09-14": {}, "2019-09-13": {}, "2019-09-12": {}, "2019-09-11": {}, "2019-09-10": {}, "2019-09-09": {}, "2019-09-08": {}, "2019-09-07": {}, "2019-09-06": {}, "2019-09-05": {}, "2019-09-04": {}, "2019-09-03": {}, "2019-09-02": {}, "2019-09-01": {}, "2019-08-31": {}, "2019-08-30": {}, "2019-08-29": {}, "2019-08-28": {}, "2019-08-27": {}, "2019-08-26": {}, "2019-08-25": {}, "2019-08-24": {}, "2019-08-23": {}, "2019-08-22": {}, "2019-08-21": {}, "2019-08-20": {}, "2019-08-19": {}, "2019-08-18": {}, "2019-08-17": {}, "2019-08-16": {}, "2019-08-15": {}, "2019-08-14": {}, "2019-08-13": {}, "2019-08-12": {}, "2019-08-11": {}, "2019-08-10": {}, "2019-08-09": {}, "2019-08-07": {}, "2019-08-06": {}, "2019-08-05": {}, "2019-08-04": {}, "2019-08-03": {}, "2019-08-02": {}, "2019-08-01": {}, "2019-07-31": {}, "2019-07-30": {}, "2019-07-29": {}, "2019-07-28": {}, "2019-07-27": {}, "2019-07-26": {}, "2019-07-25": {}, "2019-07-24": {}, "2019-07-23": {}, "2019-07-22": {}, "2019-07-21": {}, "2019-07-20": {}, "2019-07-19": {}, "2019-07-18": {}, "2019-07-17": {}, "2019-07-16": {}, "2019-07-15": {}, "2019-07-14": {}, "2019-07-13": {}, "2019-07-12": {}, "2019-07-11": {}, "2019-07-10": {}, "2019-07-09": {}, "2019-07-08": {}, "2019-07-07": {}, "2019-07-06": {}, "2019-07-05": {}, "2019-07-04": {}, "2019-07-03": {}, "2019-07-02": {}, "2019-07-01": {}, "2019-06-30": {}, "2019-06-29": {}, "2019-06-28": {}, "2019-06-27": {}, "2019-06-26": {}, "2019-06-25": {}, "2019-06-24": {}, "2019-06-23": {}, "2019-06-22": {}, "2019-06-21": {}, "2019-06-20": {}, "2019-06-19": {}, "2019-06-18": {}, "2019-06-17": {}, "2019-06-16": {}, "2019-06-15": {}, "2019-06-14": {}, "2019-06-13": {}, "2019-06-12": {}, "2019-06-11": {}, "2019-06-10": {}, "2019-06-09": {}, "2019-06-08": {}, "2019-06-07": {}, "2019-06-06": {}, "2019-06-05": {}, "2019-06-04": {}, "2019-06-03": {}, "2019-06-02": {}, "2019-06-01": {}, "2019-05-31": {}, "2019-05-30": {}, "2019-05-29": {}, "2019-05-28": {}, "2019-05-27": {}, "2019-05-26": {}, "2019-05-25": {}, "2019-05-24": {}, "2019-05-23": {}, "2019-05-22": {}, "2019-05-21": {}, "2019-05-20": {}, "2019-05-19": {}, "2019-05-18": {}, "2019-05-17": {}, "2019-05-16": {}, "2019-05-15": {}, "2019-05-14": {}, "2019-05-13": {}, "2019-05-12": {}, "2019-05-11": {}, "2019-05-10": {}, "2019-05-09": {}, "2019-05-08": {}, "2019-05-07": {}, "2019-05-06": {}, "2019-05-05": {}, "2019-05-04": {}, "2019-05-03": {}, "2019-05-02": {}, "2019-05-01": {}, "2019-04-30": {}, "2019-04-29": {}, "2019-04-28": {}, "2019-04-27": {}, "2019-04-26": {}, "2019-04-25": {}, "2019-04-24": {}, "2019-04-23": {}, "2019-04-22": {}, "2019-04-21": {}, "2019-04-20": {}, "2019-04-19": {}, "2019-04-18": {}, "2019-04-17": {}, "2019-04-15": {}, "2019-04-14": {}, "2019-04-13": {}, "2019-04-12": {}, "2019-04-11": {}, "2019-04-10": {}, "2019-04-09": {}, "2019-04-07": {}, "2019-04-06": {}, "2019-04-05": {}, "2019-04-04": {}, "2019-04-03": {}, "2019-04-02": {}, "2019-04-01": {}, "2019-03-31": {}, "2019-03-30": {}, "2019-03-29": {}, "2019-03-28": {}, "2019-03-26": {}, "2019-03-25": {}, "2019-03-24": {}, "2019-03-23": {}, "2019-03-22": {}, "2019-03-21": {}, "lastDeltaAv": 9.6640625, "2020-07-08": {}}